2023 - Research.com Neuroscience in United Kingdom Leader Award
Karl Herholz spends much of his time researching Positron emission tomography, Pathology, Dementia, Alzheimer's disease and Nuclear medicine. The various areas that he examines in his Positron emission tomography study include Internal medicine, Tomography, Glioma and Stereotaxic technique. His Internal medicine research integrates issues from Endocrinology, Oncology and Cardiology.
His Disease and Brain tumor study in the realm of Pathology interacts with subjects such as Gadolinium. His Dementia research is multidisciplinary, incorporating elements of Differential diagnosis, Central nervous system disease, Degenerative disease and Posterior cingulate. His study in Alzheimer's disease is interdisciplinary in nature, drawing from both Cognition, Neuropsychology, Audiology, Cortex and Biomarker.
His main research concerns Positron emission tomography, Internal medicine, Nuclear medicine, Pathology and Neuroscience. The concepts of his Positron emission tomography study are interwoven with issues in Basal ganglia, Carbohydrate metabolism, Magnetic resonance imaging and Dementia. His work deals with themes such as Differential diagnosis, Biomarker and Cognition, which intersect with Dementia.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology, Oncology and Cardiology. His Nuclear medicine research incorporates themes from Voxel, Tomography and Glioma. His work focuses on many connections between Alzheimer's disease and other disciplines, such as Posterior cingulate, that overlap with his field of interest in Precuneus.
Positron emission tomography, Pathology, Dementia, Disease and Nuclear medicine are his primary areas of study. His Positron emission tomography research is multidisciplinary, relying on both Preclinical imaging, Molecular imaging, Apolipoprotein E and Asymptomatic. His Pathology research includes themes of Grey matter and Glioma.
His research in Dementia intersects with topics in Cognition, Neuroscience, Differential diagnosis, Alzheimer's disease and Amyloid. His Disease study is focused on Internal medicine in general. His Nuclear medicine research includes elements of White matter and Iterative reconstruction.
Karl Herholz mostly deals with Positron emission tomography, Pathology, Biomarker, Disease and Dementia. His work in the fields of Positron emission tomography, such as Binding potential, overlaps with other areas such as Clinical diagnosis. His Pathology study combines topics from a wide range of disciplines, such as Molecular imaging, Microglia and Glioma.
His Biomarker research incorporates elements of Alzheimer's disease, Neuroimaging, Nuclear medicine and Clinical validity. His work carried out in the field of Disease brings together such families of science as Cerebral glucose metabolism, Clinical trial, Oncology and Intensive care medicine. His research brings together the fields of Endocrinology and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography : Review and 1999 EORTC recommendations
H. Young;R. Baum;U. Cremerius;K. Herholz.
European Journal of Cancer (1999)
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Karl Herholz;Eric Salmon;Daniela Perani;Jean-Claude Baron.
Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias
Lisa Mosconi;Wai H. Tsui;Wai H. Tsui;Karl Herholz;Alberto Pupi.
The Journal of Nuclear Medicine (2008)
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Harald Hampel;Richard Frank;Karl Broich;Stefan J. Teipel.
The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders.
Volker Sturm;Doris Lenartz;Athanasios Koulousakis;Harald Treuer.
Journal of Chemical Neuroanatomy (2003)
Progressive derangement of periinfarct viable tissue in ischemic stroke.
W.-D. Heiss;M. Huber;G. R. Fink;K. Herholz.
Journal of Cerebral Blood Flow and Metabolism (1992)
11C-methionine PET for differential diagnosis of low-grade gliomas
K. Herholz;T. Hölzer;B. Bauer;R. Schröder.
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Giovanni B Frisoni;Marina Boccardi;Frederik Barkhof;Kaj Blennow;Kaj Blennow.
Lancet Neurology (2017)
MCI conversion to dementia and the APOE genotype A prediction study with FDG-PET
L. Mosconi;D. Perani;S. Sorbi;Karl Herholz.
An Interactive Technique for Three-Dimensional Image Registration: Validation for PET, SPECT, MRI and CT Brain Studies
Uwe Pietrzyk;Karl Herholz;Gereon Fink;Andreas Jacobs.
The Journal of Nuclear Medicine (1994)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: